August 15
CUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read more
Brandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between major Australian superannuation funds, CSL, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areVaxxas' proprietary Nanopatch™ technology is a needle-free vaccine delivery solution
View ProjectDeveloping a new class of therapeutics that enhance the function of beneficial proteins
View ProjectTargeting long non-coding RNAs for next generation cancer therapies
View ProjectThe University of Queensland's Australian Institute for Bioengineering and Nanotechnology (AIBN) is an integrated multi-disciplinary research institute bringing together the skills of world-class researchers in the areas of bioengineering and nanotechnology.
ViewThe Australian Institute of Tropical Health and Medicine (AITHM) is a multi-disciplinary health and tropical medicine research institute located in the tropics. Based at James Cook University in northern Queensland, AITHM has key nodes in Townsville, Cairns and the Torres Strait.
ViewWe conduct eye research with real-life impact. We are unravelling the causes of diseases, preventing blindness through earlier diagnosis and better treatments, and restoring sight.
ViewBrandon BioCatalyst is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we partner with entrepreneurs to create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreCUREator+ delivers $50m funding boost to commercially focused BioMedTech startups
Read moreVaxxas Announces Interim Phase I Study Results for First Needle-Free HD-MAP COVID-19 Vaccine
Read more